SAN DIEGO, Jan. 3, 2020 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 38th
Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16 at 8:30 a.m. PT / 11:30 a.m.
ET. Dr. Helen Torley,
president and chief executive officer, will provide a corporate
overview.
The presentation will be webcast through the "Investors" section
of Halozyme's corporate website at www.halozyme.com, and a
recording will be made available for 90 days following the event.
To access a live webcast, please visit Halozyme's website
approximately 15 minutes prior to the presentation to register and
download any necessary audio software.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on
novel biological and drug delivery approaches. Halozyme's
proprietary enzyme rHuPH20 is used to facilitate the delivery of
injected drugs and fluids and potentially reduce the treatment
burden of other drugs to patients. Halozyme has licensed its
rHuPH20 technology, called ENHANZE®, to leading pharmaceutical and
biotechnology companies including Roche, Baxalta, Pfizer, Janssen,
AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme
derives revenues from these collaborations in the form of
milestones and royalties as the Company's partners make progress
developing and commercializing their products being developed with
ENHANZE®. Halozyme is headquartered in San Diego. For more information visit
www.halozyme.com.
Contact:
Al
Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-present-at-the-38th-annual-jp-morgan-healthcare-conference-300980600.html
SOURCE Halozyme Therapeutics, Inc.